Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-08
2005-02-08
Huang, Evelyn (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S299000, C514S339000, C514S413000, C514S363000, C514S364000, C514S372000, C514S380000, C514S369000, C514S376000, C514S393000, C540S582000, C540S585000, C546S112000, C546S276700, C548S452000, C548S228000, C548S229000, C548S142000, C548S144000, C548S213000, C548S243000, C548S181000, C548S312100
Reexamination Certificate
active
06852716
ABSTRACT:
The invention provides compounds of Formula I:These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.
REFERENCES:
patent: 3702324 (1972-11-01), Skinner et al.
patent: 4093734 (1978-06-01), Kruger et al.
patent: 4593034 (1986-06-01), Munson, Jr. et al.
patent: 4605652 (1986-08-01), Welstead, Jr.
patent: 4657911 (1987-04-01), Imbert et al.
patent: 4717563 (1988-01-01), Alphin et al.
patent: 4721720 (1988-01-01), Wootton et al.
patent: 4798829 (1989-01-01), King et al.
patent: 4803199 (1989-02-01), Donatsch et al.
patent: 4820715 (1989-04-01), Monkovic et al.
patent: 4835162 (1989-05-01), Abood
patent: 4870181 (1989-09-01), Lo
patent: 4877780 (1989-10-01), Vega-Noverola et al.
patent: 4877794 (1989-10-01), Naylor et al.
patent: 4908370 (1990-03-01), Naylor et al.
patent: 5017580 (1991-05-01), Naylor et al.
patent: 5025022 (1991-06-01), Naylor et al.
patent: 5039680 (1991-08-01), Impoerato et al.
patent: 5057519 (1991-10-01), Suberg
patent: 5070095 (1991-12-01), Jagdmann, Jr. et al.
patent: 5084460 (1992-01-01), Munson, Jr. et al.
patent: 5106843 (1992-04-01), Ward et al.
patent: 5175173 (1992-12-01), Sun
patent: 5206246 (1993-04-01), Langlois et al.
patent: 5236931 (1993-08-01), Jagdmann et al.
patent: 5237066 (1993-08-01), Dorme et al.
patent: 5273972 (1993-12-01), Jagdmann et al.
patent: 5561149 (1996-10-01), Azria et al.
patent: 5723103 (1998-03-01), de Paulis et al.
patent: 5919793 (1999-07-01), Brown et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 20030055043 (2003-03-01), Jacobsen et al.
patent: 2625678 (1988-01-01), None
patent: WO 9109593 (1991-07-01), None
patent: WO 9211259 (1992-07-01), None
patent: WO 9215579 (1992-09-01), None
patent: WO 9730998 (1997-08-01), None
patent: WO 0073431 (2000-12-01), None
patent: WO0129034 (2001-04-01), None
patent: WO 0136417 (2001-05-01), None
patent: WO0160821 (2001-08-01), None
patent: WO 0176576 (2001-10-01), None
Bannon, A.W.,American Association for the Advancement of Science.Broad-Spectrum, Non-Opiodid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors. vol. 279, No 5347, pp. 77-81, 1998.
Dineley, K.T., and James W. Patrick,The Journal of Biological Chemistry.Amino Acid Determinants of •7 Nicotinic Acetylcholine Receptor Surface Expression. vol. 275, No 18, pp. 13974-13985, May 5, 2000.
Eisele, Jean-Luc.Letters to Nature.Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. vol. 366, pp. 479-483, Dec. 2, 1993.
Holladay, Mark W., et. al.,Journal of Medicinal Chemistry.Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery. Dec. 19, 1997.
Kem, William R.Behavioral Brian Research.“The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).” 113 (2000) 169-181.
Kuntzweiler, Theresa A., et. al.Drug Development Research.“Rapid Assessment of Ligand Actions with Nicotinic Acetylcholine Receptors Using Calcium Dynamics and FLIPR.” vol. 44, No. 1, pp. 14-20, May 1998.
Macor, JE.Bioorganic&Medicinal Chemistry Letters.“The 5-HTsAntagonist Tropisetron ( ICS 205-930) is a Potent and Selective α7 Nicotinic Receptor Partial Agonist.” 11 (2001) 319-321.
Acker Brad A.
Groppi, Jr. Vincent E.
Jacobsen Eric Jon
Myers Jason K.
Piotrowski David W.
Dorigo Andrea E.
Huang Evelyn
Ling Lorraine B.
Pfizer Inc
Richardson Peter C.
LandOfFree
Substituted-aryl compounds for treatment of disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted-aryl compounds for treatment of disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted-aryl compounds for treatment of disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464820